310 Efficacy and safety of abrocitinib in biologic-exposed versus biologic-naïve patients with moderate-to-severe atopic dermatitis

Abrocitinib, an oral once-daily Janus kinase 1 selective inhibitor, is being investigated for the treatment of moderate-to-severe atopic dermatitis (AD). This post hoc analysis evaluated if prior with biologic therapy affects response to abrocitinib. Data from patients (pts) with/without previous each arm (abrocitinib 200 mg or 100 mg, placebo) phase 2b (NCT02780167) and 3 JADE MONO-1 (NCT03349060) MONO-2 (NCT03575871) studies were pooled separately REGIMEN (NCT03627767) open-label induction mg). Investigator’s Global Assessment score 0/1 (IGA 0/1) ≥2-grade improvement baseline ≥75% in Eczema Area Severity Index (EASI-75) assessed. IGA rates among 67/867 pts 43.5%/41.4% mg), 24.1%/26.7% 0%/8.5% (placebo) population, 53.5%/66.9% mg) 86/1147 REGIMEN. EASI-75 65.2%/62.4% 34.5%/42.7% 7.1%/12.7% 64.0%/76.4% Treatment-emergent adverse event 71.7%/69.9% + arms) 66.3%/66.5% Abrocitinib efficacy safety consistent AD regardless therapy.